SAR Sareum Drug Discovery Co.

The last FY loss was £0.75m before a tax credit: I'd beware of looking at just H2, as stuff can be booked arbitrarily in either HY, messing up the predictions.

However, Seymour Pierce have a profit forecast of £50,000 for the FY to next June, so there might be something in the notion that they are currently breaking even.

MCap is about £3m, and NTA £1.2m.

As pointed out, they need some 'conclusion news' - viz. cash inflow.

I'm not tempted, but mainly the spread on shares priced at less than 1p is a serious downer.